Alphamab Oncology Sustainability Profile
Alphamab Oncology, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative cancer therapies. Founded in 2016, the company has rapidly established itself in the oncology sector, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in both domestic and international markets, Alphamab Oncology has achieved significant milestones, including the successful development of its proprietary drug candidates. Their core products, distinguished by their unique mechanisms of action, aim to address unmet medical needs in cancer treatment. Recognised for its commitment to advancing oncology solutions, Alphamab Oncology continues to strengthen its market position through strategic partnerships and a robust pipeline, making it a notable player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Alphamab Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alphamab Oncology's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alphamab Oncology's reported carbon emissions
In 2024, Alphamab Oncology reported total carbon emissions of approximately 13,821,490 kg CO2e, comprising 4,022,890 kg CO2e from Scope 1 emissions and 9,798,600 kg CO2e from Scope 2 emissions. This marks a slight increase from 2023, where total emissions were about 12,760,800 kg CO2e, with Scope 1 at 3,969,510 kg CO2e and Scope 2 at 8,791,300 kg CO2e. The company has consistently disclosed emissions data for Scope 1 and Scope 2 but has not reported any Scope 3 emissions. Alphamab Oncology has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests a need for further development in their climate strategy. Overall, while Alphamab Oncology has made strides in transparency regarding its emissions, the lack of reduction commitments indicates an opportunity for improvement in its climate action framework.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 75,810 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 798,260 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is Alphamab Oncology's Industry?
How Carbon Intensive is Alphamab Oncology's Location?
Alphamab Oncology's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alphamab Oncology has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
